Corporate Overview | Management Team | Scientific Advisors



The ImmuRx team combines expertise in adjuvant engineering, drug development, clinical trial execution, business development and intellectual property protection.

David DeLucia  

David DeLucia, Chief Executive Officer

Mr. DeLucia has over 20 years experience in the biopharmaceutical industry including evaluation of emerging technologies, leading technical development which is focused on business goals, organizational development of drug development enterprises, and the development and management of strategic partnerships. Mr. DeLucia was CEO of MIST Inc., a breast cancer imaging company. Prior to MIST, he led the development of a genomics based technology platform at Millennium Pharmaceuticals which was spun out as part of a separate company in 2003. He has an M.S. from MIT and a B.A. from Dartmouth College.


Randolph Noelle


Randolph Noelle, Ph.D, Chief Scientific Officer

Dr. Noelle is co-Director of the Immunology and Cancer Immunotherapy Program of the Norris Cotton Cancer Center and Chair of the Microbiology and Immunology Department at Dartmouth Medical School. His laboratory discovered the natural CD40 ligand, CD154, and produced therapeutic antibodies for the treatment of a wide spectrum of autoimmune diseases, subsequently licensed to IDEC/Biogen. He has lead the design and analysis of numerous clinical trials.  Dr. Noelle is in the top 5% of NIH funded scientists for total funding over his career.


Susan Dana Jones


Susan Dana Jones, Ph.D., Vice President of Research & Development

Susan Dana Jones, Ph.D., has more than 20 years of discovery, product development, and strategic planning experience in biotechnology. She co-founded two biotechnology companies, Waratah Pharmaceuticals and Serenex, Inc and has managed discovery and product development programs in multiple organizations and for multiple disease areas. Dr. Jones received her Bachelor's degree from Harvard University, her Ph.D. from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.


Ross Kedl


Ross Kedl, Ph.D, Director of Research

Dr. Kedl is experienced in early drug discovery, development, and lead optimization. Before joining the Faculty at the University of Colorado, Dr. Kedl was with 3M Pharmaceuticals working on their small molecule immune response modifier program.  While there, he spearheaded their efforts at developing novel vaccine adjuvants, resulting in 10 separate patents in just 3 years.  With 6 publications and 3 patents filed since joining the University of Colorado Department of Immunology in 2004, Ross continues to discover and develop commercially significant adjuvants.


Cory Ahonen


Cory Ahonen, Senior Scientist

Mr. Ahonen has over 12 years experience in both academic and industrial scientific research.  Currently, his research focuses on the development of novel cancer vaccines for melanoma.  Prior to joining Dr. Randolph Noelle's laboratory at Dartmouth Medical School, Mr. Ahonen was a Research Scientist in the Drug Discovery division of 3M Pharmaceuticals.  Here, he pioneered research on the mechanism of action of their small molecule immune response modifiers.  Mr. Ahonen holds a degree in chemistry from Macalester College, is an inventor on four patent filings and lead author on numerous manuscripts including publications in Journal of Experimental Medicine and Nature Immunology.


Robin Teskin


Robin Teskin, Partner, Hunton & Williams, LLP

Ms. Teskin's experience includes patent prosecution worldwide on behalf of Idec Pharmaceuticals relating to the first recombinant antibody approved for treatment of cancer (Rituxan) and the first radio-labeled antibody for treatment of cancer (Zevalin). She co-represented Dartmouth College in a landmark interference case relating to a therapeutic antibody for the treatment of autoimmune disorders (Noelle v. Lederman). Earlier, as a patent examiner at the U.S. Patent and Trademark Office, Ms. Teskin issued several hundred patents dealing with complex biotechnology research, received a Bronze Medal for distinguished federal service, and was elected to issue U.S. Patent Number 5,000,000.



    © Copyright 2008 All Rights Reserved Site Map Site Designed By: Kristy Ford Creative